Novartis provides updates on its leading research and development (R&D) pipeline
Novartis R&D Day 2012 held on November 8th in Cambridge, MA, (USA) is an Investor event with senior Novartis executives discussing developments in research and development (R&D) across its divisions including Oncology and Pharmaceuticals. Key executives presented the Company's pipeline highlighting exciting new therapeutic areas for the Company.
“As a science-driven company, Novartis is focused on innovation to address unmet medical needs for patients around the world.”
– Joseph Jimenez, CEO of Novartis.
“As a result, our leading pipeline in all phases of development positions us well for continued future growth.” Novartis has a strong commitment to new drug development with an industry-leading pipeline. The Company has introduced dozens of new drugs and continues to work to address unmet medical needs.
At Novartis, our strategy is to grow and thrive through science based innovation. Innovation is critical for us. By focusing on the patient and following the science, Novartis has discovered innovative treatments for a wide variety of disorders. Thanks to this approach, Novartis has one of the industry-leading pipelines with 139 projects in clinical development with more than 73 New Molecular Entities (NMEs) across a multitude of disease areas.
Related links and documents:
Disclaimer:
This article may contain forward looking statements. Please see the disclaimer included in our media release.
